Pharmaceutical firm Phapros (PEHA) booked profit attributable to owner of Rp132.3 billion in 2018, grew 5.6% from Rp125.2 billion in 2017. Net sales inched up 2% to Rp1.02 trillion, and the cost of goods sold rose 6.8% to Rp440 billion. The Company also recorded higher general and administrative expenses (Rp120 billion), and higher finance charges (Rp40 billion). It also booked other income of Rp30 billion.
To subscribe please click here
